Pharmaceutical Monitoring of Drugs

[dropdown] [dropdown-option] SELECT ONE…[/dropdown-option] [dropdown-option value=”option5″] Analgesics [/dropdown-option] [dropdown-option value=”option1″] Angiotensin Converting Enzyme Inhibitors (ACE-Is) [/dropdown-option] [dropdown-option value=”option2″] HMG CO-A Reductase inhibitors (Statins) [/dropdown-option] [dropdown-option value=”option3″] Nonsteroidal Aromatase Inhibitor—Inhibitor of Estrogen Biosynthesis—Antitumor Agent [/dropdown-option] [dropdown-option value=”option4″] Oral Antidiabetics [/dropdown-option] [/dropdown] [dropdown-content value=”option5″]

*Analgesics*
Class of Medication	Medication		*Parameter*	Value	Time-frame
Gamma aminobutyric acid (GABA) analogues	Pregabalin	Efficacy	Monitor closely for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression. Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Fibromyalgia, and Spinal Cord Injury Pain: Assess location, characteristics, and intensity of pain periodically during therapy. Seizures: Assess location, duration, and characteristics of seizure activity. Lab Test Considerations: May cause ↑ creatine kinase levels. May cause↓ platelet count.
		Safety

[/dropdown-content] [dropdown-content value=”option1″]

*Angiotensin Converting Enzyme Inhibitors (ACE-Is)*
Medication		*Parameter*	Value	Time-frame
Ramipril	Efficacy	BP	<130/80	Titrate medications every 2 weeks to achieve target
	Safety	K	3.5-5.0 (WNL)	1 Month
		Dry Cough	Tolerable or ideally none	1 Week
		Signs of hypotension: Dizziness, Headache, SBP <100	None	In two weeks and at each visit

[/dropdown-content] [dropdown-content value=”option2″]

*HMG CO-A Reductase inhibitors (Statins)*
Medication		*Parameter*	Value	Time-frame
Atorvastatin	Efficacy	LDL cholesterol	< 2 mmol/L (or 1.8 mmol/L)	8-12 Weeks
	Safety	Muscle aches (not related to activity)	None	Monitor at next visit
		ALT	WNL	If patient complains of GI tenderness / pain, jaundice
		CK	WNL	If patient complains of muscle aches not related to activity

[/dropdown-content] [dropdown-content value=”option4″]

*Oral Antidiabetics*
Class	Medication		*Parameter*	Value	Time-frame
Dipeptidyl peptidase-4 (DPP-4)	Sitagliptin		Observe the patient for signs and symptoms of hypoglycemic reactions (abdominal pain, sweating, hunger, weakness, dizziness, headache, tremor, tachycardia, anxiety). Monitor for signs of pancreatitis (nausea, vomiting, anorexia, persistent severe abdominal pain, sometimes radiating to the back) during therapy. If pancreatitis occurs, discontinue sitagliptin and monitor serum and urine amylase, amylase/creatinine clearance ratio, electrolytes, serum calcium, glucose, and lipase. Assess for rash periodically during therapy. May cause Stevens-Johnson syndrome. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis, and/or eosinophilia. Lab Test Considerations: Monitor hemoglobin A1C prior to and periodically during therapy. Monitor renal function prior to and periodically during therapy.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors	Empagliflozin (Jardiance)	Efficacy	Hemoglobin A1c (HbA1c)		Every 3-6 Months
		Safety	Blood Pressure
			Renal function
			Genital Mycotic Infection
			Pregnancy Test	Negative	Contraindicated in 2nd and 3rd Trimesters
			Urinary Tract Infection

[/dropdown-content] [dropdown-content value=”option3″]

Nonsteroidal Aromatase Inhibitor—Inhibitor of Estrogen Biosynthesis—Antitumor Agent
Medication		*Parameter*	Value	Time-frame
Atorvastatin	Efficacy
	Safety	Check vital signs and assess cardiovascular and respiratory status. Monitor renal and hepatic function, electrolyte levels, and lipid panels. Assess for adverse CNS effects, including depression. Institute safety measures as needed to prevent injury.